Disease Description:
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a bacterium responsible for several difficult-to-treat infections in humans. It may also be referred to as multidrug-resistant Staphylococcus aureus or oxacillin-resistant Staphylococcus aureus (ORSA). MRSA is by definition any strain of Staphylococcus aureus bacteria that is resistant to a large group of antibiotics called the beta-lactams, which include the penicillins and the cephalosporins.
MRSA has adapted to survive treatment with beta-lactam antibiotics, including methicillin, dicloxacillin, nafcillin, and oxacillin. MRSA is especially troublesome in hospital-associated (nosocomial) infections. In hospitals, patients with open wounds, invasive devices, and weakened immune systems are at greater risk for infection than the general public. Hospital staff who do not follow proper sanitary procedures may transfer bacteria from patient to patient. Visitors to patients with MRSA infections or MRSA colonization are advised to follow hospital isolation protocol by using gloves, gowns, and masks when indicated. Visitors, including health care providers, who do not follow such protocols are capable of spreading the bacteria to areas such as cafeterias, bathrooms, elevators, or various other surfaces.
Current Treatment:
Currently MRSA is treated with a variety of antibiotic treatments. However, as more and more anitibiotic resistant strains emerge, medical professional struggle to find treatments to circumvent the resistance.
Evidence for Cannabinoids:
Cannabinoids have long been known to have antibacterial properties, and in one study at the Università del Piemonte Orientale, all 5 major cannabinoids (cannabinol, cannabichromene, cannabigerol, Delta (9)-tetrahydrocannabinol, and cannabinol) showed "potent activity against a variety of Methicillin-Resistant Staphylococcus Aureus (MRSA) strains of current clinical relevance."
Proposed Mechanism for Cannabinoid Therapeutics
While the evidence shows a highly potent antibiotic effect, scientists are unable to explain the mechanism of activity. - Rahman M. et al., Antibacterial Cannabinoids from Cannabis Sativa: A Structure - Activity Study. J. Nat. Prod. 2008, 71, 1427–1430
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Can you advise us as to when the original CBIS stock will be converted and what will the new stock be listed under - its ticker symbol.
Good Afternoon, Guys! Do we EVER have an Update for you, as stated earlier, 2024 is our Year! We are in the process of closing a couple of new...Good Afternoon, Guys! Do we EVER have an Update for you, as stated earlier, 2024 is our Year! We are in the process of closing a couple of new Partnership deals for Cannabis Science and our Expedited cancer drug development program. We are still working on the paperwork, but we can certainly start Thanking God now! That is for sure! We will be putting News Releases out in each respective Public Company and continue our FDA quest for an IND# so we can start Phase 1 Clinical Studies for Killing these Nasty Cancers.
As mentioned earlier, we will shut down the CSi-VIP Legacy Drug Ownership Program as soon as we close the first deal, the paperwork is forthcoming. We are still working on the investment reports for ALL our CSi-VIPs as stated, so you still have time to purchase your personal share of the CSi-Legacy Cancer Drug! It has certainly been a long time coming!
If you are NOT a CSi-VIP and you are interested in directly owning a piece of our CSi-Legacy Drug, it’s NOT too late for you either!
The CSi-VIP Legacy Drug Ownership Program links are all Live and updated, if you have any questions, Please feel free to contact me directly for ALL your options available this week.
*** Send me an email with your questions and contact info.
raymond.dabney@cannabisscience.com
Ps … For ALL of you sending emails “feeling off” about our continuous CSi-VIP Gifts and Offerings. Maybe you will be more comfortable if we start selling some of our own Shiny Sneakers, Bibles, Bobbleheads, NFTs, Coins, Hats, Socks, Coffee Mugs, Stickers, Calendars, Inflatable Pool Toys, Trading Cards, Toilet Paper, a Hat with MY Hair, Posters, Signed Autographs, Chia Pet Head, Flags, Clocks, Pins, and I’m sure we can come up with many more creative Fun Items. So, in the near Future, we will open our own “1 Million Strong-CSi-iCannabinoid-ASU Gift Shop” for EVERYONE to take your pick of our own Branded Merchandise for your enjoyment and specialty items collection.
*** Right now, with our CSi-VIP offerings, you Only need to KNOW that ALL your funding is going towards the continuous Successful operations required to bring our “Low-Cost, CSi-Cancer Killing Drugs” to market ASAP. You are a BIG part of the Key to Make that Change. So, let’s make sure you are a CSi-Legacy Drug Owner before that door closes too, that is the Best I can say, for now.
Good Bless us ALL.
Talk soon Guys.
Raymond - IGWT
raymond.dabney@cannabisscience.com
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Hey Mike good morning! Hope all is well for you! Sorry for the delayed response I know this is your second poke! Once... Show more 1 week ago